Gwendolyn Binder

Dr. Binder joined Cabaletta Bio in February 2019 as one of Cabaletta’s first employees and established the preclinical, translational, manufacturing and quality organizations. As President of Science and Technology, Dr. Binder is responsible for establishing and executing strategies in research and manufacturing to deliver competitive and transformative cellular therapeutics for patients with autoimmune disease.

In addition to her position at Cabaletta Bio, she serves on the Board of Directors of Instil Bio, a company developing novel cancer immunotherapies, and as a member of the Scientific Advisory Board for Immatics, which is a publicly traded company developing engineered T cell immunotherapy for cancer.

Prior to joining Cabaletta, Dr. Binder was the Chief Technology Officer of Adaptimmune Therapeutics Plc, where she established early clinical, translational research and manufacturing functions in the U.S. arm of the company, including providing oversight on the build out of a commercial scale cell therapy manufacturing facility, and ultimately transitioned to lead the research team to focus on prioritizing next generation products and novel targets in early clinical development.

Earlier in her career, Dr. Binder served as Director of Operations for the Translational Research Program at the University of Pennsylvania, where she progressed multiple Investigational New Drug (“IND”) applications for novel engineered T-cell therapies in human immunodeficiency (“HIV”) and oncology, including the CD19 CAR IND acquired by Novartis (now Kymriah®), the first human gene editing IND, and three TCR engineered T cell therapy studies in oncology and HIV.

Prior to that, she served as the Director of Scientific Affairs at VIRxSYS Corporation in Gaithersburg, Maryland, where she supported the development of the first clinical lentiviral vector used in humans.

Dr. Binder studied viral immunology and translational research at Johns Hopkins University in Baltimore, USA, where she earned a Ph.D. in Cellular and Molecular Medicine in 2002. She has authored over 30 publications in the field, including top international journals such as “Science” and “Nature Medicine.” She is a recognized leader in the biotechnology sector for the translational and clinical advancement of novel T cell therapies for patients with serious diseases.